The EMERGE team is very excited to introduce POEM – a retrospective multi-centre observational study.
Acute pain is one of the most common reasons for Emergency Department (ED) attendance yet adequate pain management remains an issue recognised as an area in need of improvement.
Recent Audits undertaken by The Royal College of Emergency Medicine (RCEM) in 2012 concluded that a wide variation of performance exists between EDs across the UK. They concluded that that the “timely administration of analgesia remains a challenge across the UK and that ongoing vigilance is required in this area”.
Numerous other studies have shown that ED overcrowding, patient’s ethnicity, socio-economic class, age, gender etc., are factors that can affect delivery of analgesia.
POEM aims to assess the adequacy of pain management in patients presenting to the ED with confirmed long bone fracture and/or dislocation isolated to a proximal or distal limb.
Its secondary aim is to assess the influence of pain management on the following factors; age, gender, ethnicity, socioeconomic class, departmental overcrowding and daily departmental quality indicators.
The data collected within this study will allow the assessment of the timing and delivery of analgesia during a typical ED period across major EDs within the UK. It hopes to highlight factors associated with the failure to provide effective and timely analgesia, in the hopes that the results will inform further targeted research, ultimately improving patient care within this group.
Trial Design: Retrospective Multi-centre, Observational Study
Eligibility Criteria: All Adult and Paediatric patients with confirmed long bone fracture and/or dislocation isolated to a single proximal or distal limb presenting to ED.
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department
The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.
The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.
This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.
Participants will be asked to return for 6 visits across 12 months to evaluate their health.
Across the UK the trial aims to recruit 10,260 volunteers.
If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh
The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.